This article was originally published in Pharmaceutical Approvals Monthly
Company is preparing to submit an NDA for the Celexa follow-on product escitalopram in the first half of 2001, the firm tells analysts Jan. 16. Launch of the single-isomer version of Celexa is expected in the second half of 2002. Head-to-head data on the product will be discussed at the American Psychiatric Association meeting May 5-10 in New Orleans. Forest expects to file an NDA in mid-2001 for its hypertension product lercanidipine. The firm also plans to submit an NDA for its oxycodone/ibuprofen pain combination in 2001. Depending on the outcome of meetings with FDA in the first quarter, Forest could file an NDA as early as the second half of 2001 for the NMDA antagonist memantine for an Alzheimer's indication. Launch of the firm's non-CFC version of the asthma inhaler Aerobid (flunisolide) is expected in the fall; the NDA was submitted in April 200
You may also be interested in...
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.
As the US heads into a COVID-19 storm with grave concerns about the lack of face masks and respirators for health care workers, the FDA has further relaxed federal oversight for such products, giving more responsibility to employers
FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.